Provention Bio, Inc. (PRVB)


-0.10 (-0.40%)
Symbol PRVB
Price $23.895
Beta 2.178
Volume Avg. 2.09M
Market Cap 2.177B
Shares () -
52 Week Range 3.185-24.23
1y Target Est -
DCF Unlevered PRVB DCF ->
DCF Levered PRVB LDCF ->
ROE -99.08% Strong Sell
ROA -54.72% Strong Sell
Operating Margin -
Debt / Equity 33.95% Neutral
P/E -15.62 Strong Sell
P/B 13.72 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest PRVB news

Mr. Ashleigh W. Palmer B.Sc., M.B.A.
NASDAQ Global Select

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.